Hepatitis C virus (HCV) is one of the leading causes of chronic liver disease, cirrhosis, and
hepatocellular carcinoma, resulting in major global public health concerns. The HCV …

Background The revolution in hepatitis C virus (HCV) treatment through the development of
direct-acting antivirals (DAAs) has generated international interest in the global elimination …

Hepatitis C virus (HCV) infection, defined by active carriage of HCV RNA, affects nearly
1.0% of the worldwide population. The main risk factors include unsafe injection drug use …

Background Population‐level monitoring of hepatitis C virus (HCV) infected people across
cascades of care identifies gaps in access and engagement in care and treatment. We …

The most common causes of hepatitis worldwide is a group of viruses known as hepatitis A,
B, C, D and E virus. Most deaths from viral hepatitis are due to hepatitis B and hepatitis C …

Due to the introduction of newer, more efficacious treatment options, there is a pressing
need for policy makers and public health officials to develop or adapt national hepatitis C …

Background The combination of sofosbuvir and daclatasvir is a potent, pangenotypic
regimen suitable for mass-scale hepatitis C treatment, especially in resource-limited …

Background: To discuss a range of strategic options for China to improve the accessibility of
direct antiviral agents (DAAs) as the treatment for hepatitis C. Methods: We adopted a …

The hepatitis C virus (HCV) epidemic was forecasted through 2030 for 17 countries in Africa,
Asia, Europe, Latin America and the Middle East, and interventions for achieving the Global …

Background To study the epidemiology of chronic hepatitis C virus infection in Hong Kong
and to estimate the service gap for achieving the WHO hepatitis elimination targets of …